Related Experiment Video
Updated: Dec 20, 2025
Modeling Primary Bone Tumors and Bone Metastasis with Solid Tumor Graft Implantation into Bone
Published on: September 9, 2020
Relapsed Osteosarcoma Trial Concepts to Match the Complexity of the Disease
Damon R Reed1, Pooja Hingorani2, Peter M Anderson3,4
1Cancer Biology and Evolution Program, Adolescent and Young Adult Oncology Program, Department of Interdisciplinary Cancer Management and Sarcoma Department, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. damon.reed@moffitt.org.
Abstract:
Osteosarcoma relapses not only herald a very poor prognosis but also opportunities to treat this genetically diverse complex cancer in new ways. This review will attempt to show that the field is a rapidly evolving one in which not only cytotoxic agents but also local control strategies and the immune system can be harnessed to improve the prognosis of relapsed patients. The molecular heterogeneity and the difficulty of effectively treating most common patterns of relapse with surgery and/or radiation (lung and/or bone metastases) have been responsible for a wide variety of approaches to learning whether agents are active against osteosarcoma. This chapter will highlight past, current, and potential future approaches to provide more effective systemic therapy for the problem of recurrent metastases of osteosarcoma. These include single-agent trials with a wide variety of agents, radiopharmaceuticals, and immune therapies. Finally, how such efforts are integrated into more effective local control strategies is also discussed.
Insights
Recurrent osteosarcoma, a complex cancer, offers new treatment avenues. This review explores systemic therapies, local control, and immunotherapy to improve outcomes for relapsed patients.
Area of Science:
- Oncology
- Cancer Research
- Immunotherapy
Background:
- Osteosarcoma relapses are associated with a poor prognosis.
- The genetic diversity and heterogeneity of osteosarcoma present significant treatment challenges.
- Common relapse patterns include lung and bone metastases, often difficult to manage with surgery or radiation.
Purpose of the Study:
- To review evolving strategies for treating relapsed osteosarcoma.
- To highlight past, current, and future approaches for systemic therapy.
- To discuss the integration of systemic therapies with local control strategies.
Main Methods:
- Review of single-agent clinical trials for osteosarcoma.
- Evaluation of radiopharmaceutical therapies.
- Analysis of immune-based therapies for recurrent osteosarcoma.
Main Results:
- The field of osteosarcoma relapse treatment is rapidly advancing.
- Various cytotoxic agents, local control methods, and immunotherapies show potential.
- Integrating diverse treatment modalities is crucial for improving patient prognosis.
Conclusions:
- Improved systemic therapies are needed for recurrent osteosarcoma metastases.
- Harnessing the immune system offers a promising avenue for treatment.
- A multi-faceted approach combining systemic and local control strategies is essential for better patient outcomes.
